- Rheumatoid Arthritis Slideshow Pictures
- Take the RA Quiz
- Joint-Friendly Exercises to Reduce RA Pain Slideshow
Does Enbrel (etanercept) cause side effects?
Enbrel works by blocking tumor necrosis factor alpha (TNF alpha). TNF alpha is a protein that the body produces during when there is inflammation, the body's reaction to injury. TNF alpha promotes inflammation and its associated fever and signs (pain, tenderness, and swelling) in several inflammatory conditions including rheumatoid arthritis and ankylosing spondylitis.
Enbrel is a synthetic (man-made) protein that binds to TNF alpha. It thereby acts like a sponge to remove most of the TNF alpha from the joints and blood. This prevents TNF alpha from promoting inflammation and the fever, pain, tenderness, and swelling of joints in patients with rheumatoid or psoriatic arthritis and ankylosing spondylitis.
Common side effects of Enbrel include
- mild to moderate itching, pain, swelling and redness at the site of injection,
- dizziness, and
- nasal and throat irritation.
Serious side effects of Enbrel include
- worsening or increasing occurrence of infections, cancer, multiple sclerosis, myelitis, optic neuritis, seriously low blood counts (pancytopenia), and
- new cases or worsening of congestive heart failure.
Drug interactions of Enbrel include live vaccines, because Enbrel may reduce the response of the immune system. Combining Enbrel with anakinra or abatacept, drugs that also reduce the response of the immune system, may increase the risk of serious infections.
Studies have not been conducted with Enbrel in pregnant women. Enbrel is only used in pregnant women when there is a clear need.
What are the important side effects of Enbrel (etanercept)?
The most common side effects are:
- mild to moderate itching,
- swelling and redness at the site of injection,
- nasal and throat.
TNF alpha has an important role in the responses of the immune system to infections. Thus, blocking the action of TNF alpha with etanercept may worsen or increase the occurrence of infections such as
- bacterial sepsis,
- invasive fungal infections (such as histoplasmosis), and
- other opportunistic infections (infections that occur primarily in patients with suppressed immune systems).
Patients with serious infections should not receive etanercept, and etanercept should be discontinued if a patient develops a serious infection. Etanercept should be used with caution in patients prone to infection, such as those with advanced or poorly controlled diabetes. Children should receive their recommended immunizations before treatment with etanercept.
Some reported associated conditions may or may not be related to etanercept.
Other important side effects include:
For this reason, etanercept is not recommended for persons with preexisting disease of the central nervous system (brain and/or spinal cord) or for those with multiple sclerosis, myelitis, or optic neuritis. Additionally, rare cases of seriously low blood counts (pancytopenia) have been reported in patients using etanercept. New cases or worsening of congestive heart failure may occur.
Enbrel (etanercept) side effects list for healthcare professionals
The following serious adverse reactions are discussed in greater detail in other sections of the labeling:
- Serious Infections
- Neurologic Reactions
- Patients with Heart Failure
- Hematologic Reactions
- Hepatitis B Reactivation
- Allergic Reactions
Clinical Trials Experience
- Across clinical studies and postmarketing experience, the most serious adverse reactions with Enbrel were infections, neurologic events, CHF, and hematologic events.
- The most common adverse reactions with Enbrel were infections and injection site reactions.
- Because clinical trials are conducted under widely varying conditions, adverse reactions rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not predict the rates observed in clinical practice.
Adverse Reactions In Adult Patients With Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Or Plaque Psoriasis
- The data described below reflect exposure to Enbrel in 2219 adult patients with RA followed for up to 80 months, in 182 patients with PsA for up to 24 months, in 138 patients with AS for up to 6 months, and in 1204 adult patients with PsO for up to 18 months.
- In controlled trials, the proportion of Enbrel-treated patients who discontinued treatment due to adverse events was approximately 4% in the indications studied.
Adverse Reactions In Pediatric Patients
- In general, the adverse reactions in pediatric patients were similar in frequency and type as those seen in adult patients.
- In a 48-week clinical study in 211 children aged 4 to 17 years with pediatric PsO, the adverse reactions reported were similar to those seen in previous studies in adults with PsO. Long-term safety profile for up to 264 additional weeks was assessed in an open-label extension study and no new safety signals were identified.
- In open-label clinical studies of children with JIA, adverse reactions reported in those ages 2 to 4 years were similar to adverse reactions reported in older children.
- Infections, including viral, bacterial, and fungal infections, have been observed in adult and pediatric patients. Infections have been noted in all body systems and have been reported in patients receiving Enbrel alone or in combination with other immunosuppressive agents.
- In controlled portions of trials, the types and severity of infection were similar between Enbrel and the respective control group (placebo or MTX for RA and PsA patients) in RA, PsA, AS and PsO patients.
- Rates of infections in RA and adult PsO patients are provided in Table 3 and Table 4, respectively. Infections consisted primarily of upper respiratory tract infection, sinusitis and influenza.
- In controlled portions of trials in RA, PsA, AS and PsO, the rates of serious infection were similar (0.8% in placebo, 3.6% in MTX, and 1.4% in Enbrel/Enbrel + MTX-treated groups).
- In clinical trials in rheumatologic indications, serious infections experienced by patients have included, but are not limited to,
- In clinical trials in adult PsO patients, serious infections experienced by patients have included, but are not limited to,
- abscess and osteomyelitis.
- The rate of serious infections was not increased in open-label extension trials and was similar to that observed in Enbrel- and placebo-treated patients from controlled trials.
- In 66 global clinical trials of 17,505 patients (21,015 patient-years of therapy), tuberculosis was observed in approximately 0.02% of patients. In 17,696 patients (27,169 patient-years of therapy) from 38 clinical trials and 4 cohort studies in the U.S. and Canada, tuberculosis was observed in approximately 0.006% of patients. These studies include reports of pulmonary and extrapulmonary tuberculosis.
- The types of infections reported in pediatric patients with PsO and JIA were generally mild and consistent with those commonly seen in the general pediatric population. Two JIA patients developed varicella infection and signs and symptoms of aseptic meningitis, which resolved without sequelae.
Injection Site Reactions
- In placebo-controlled trials in rheumatologic indications, approximately 37% of patients treated with Enbrel developed injection site reactions. In controlled trials in patients with PsO, 15% of adult patients and 7% of pediatric patients treated with Enbrel developed injection site reactions during the first 3 months of treatment.
- All injection site reactions were described as mild to moderate (erythema, itching, pain, swelling, bleeding, bruising) and generally did not necessitate drug discontinuation.
- Injection site reactions generally occurred in the first month and subsequently decreased in frequency.
- The mean duration of injection site reactions was 3 to 5 days. Seven percent of patients experienced redness at a previous injection site when subsequent injections were given.
Other Adverse Reactions
Table 3 summarizes adverse reactions reported in adult RA patients. The types of adverse reactions seen in patients with PsA or AS were similar to the types of adverse reactions seen in patients with RA.
Table 3: Percent of Adult RA Patients Experiencing Adverse Reactions in Controlled Clinical Trials
|Reaction||Placebo-Controlleda (Studies I, II, and a Phase 2 Study)||Active Controlledb (Study III)|
(N = 152)
(N = 349)
(N = 217)
(N = 415)
|Percent of Patients||Percent of Patients|
|Upper Respiratory Infectionse||30||38||70||65|
|Non-upper Respiratory Infections||15||21||59||54|
|Injection Site Reactions||11||37||18||43|
|a Includes data from the 6-month study in which patients received concurrent MTX therapy in both arms.|
b Study duration of 2 years.
c Any dose.
d Includes bacterial, viral and fungal infections.
e Most frequent Upper Respiratory Infections were upper respiratory tract infection, sinusitis and influenza.
In placebo-controlled adult PsO trials, the percentages of patients reporting adverse reactions in the 50 mg twice a week dose group were similar to those observed in the 25 mg twice a week dose group or placebo group.
Table 4 summarizes adverse reactions reported in adult PsO patients from Studies I and II.
Table 4: Percent of Adult PsO Patients Experiencing Adverse Reactions in Placebo-Controlled Portions of Clinical Trials (Studies I & II)
(N = 359)
(N = 876)
|Percent of Patients|
|Non-upper Respiratory Infections||14||12|
|Upper Respiratory Infectionsc||17||17|
|Injection Site Reactions||6||15|
|a Includes 25 mg subcutaneous (SC) once weekly (QW), 25 mg SC twice weekly (BIW), 50 mg SC QW, and 50 mg SC BIW doses.|
b Includes bacterial, viral and fungal infections.
c Most frequent Upper Respiratory Infections were upper respiratory tract infection, nasopharyngitis and sinusitis.
- As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay.
- Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.
- For these reasons, comparison of the incidence of antibodies to etanercept in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.
- Patients with RA, PsA, AS or PsO were tested at multiple time points for antibodies to etanercept.
- Antibodies to the TNF receptor portion or other protein components of the Enbrel drug product were detected at least once in sera of approximately 6% of adult patients with RA, PsA, AS or PsO.
- These antibodies were all non-neutralizing. Results from JIA patients were similar to those seen in adult RA patients treated with Enbrel.
- In adult PsO studies that evaluated the exposure of etanercept for up to 120 weeks, the percentage of patients testing positive at the assessed time points of 24, 48, 72 and 96 weeks ranged from 3.6%-8.7% and were all non-neutralizing.
- The percentage of patients testing positive increased with an increase in the duration of study; however, the clinical significance of this finding is unknown. No apparent correlation of antibody development to clinical response or adverse events was observed.
- The immunogenicity data of Enbrel beyond 120 weeks of exposure are unknown.
- In pediatric PsO studies, approximately 10% of subjects developed antibodies to etanercept by Week 48 and approximately 16% of subjects developed antibodies to etanercept by Week 264.
- All of these antibodies were non-neutralizing. However, because of the limitations of the immunogenicity assays, the incidence of binding and neutralizing antibodies may not have been reliably determined.
- The data reflect the percentage of patients whose test results were considered positive for antibodies to etanercept in an ELISA assay, and are highly dependent on the sensitivity and specificity of the assay.
- Patients with RA had serum samples tested for autoantibodies at multiple time points.
- In RA Studies I and II, the percentage of patients evaluated for antinuclear antibodies (ANA) who developed new positive ANA (titer ≥ 1:40) was higher in patients treated with Enbrel (11%) than in placebo-treated patients (5%).
- The percentage of patients who developed new positive anti-double-stranded DNA antibodies was also higher by radioimmunoassay (15% of patients treated with Enbrel compared to 4% of placebo-treated patients) and by Crithidia luciliae assay (3% of patients treated with Enbrel compared to none of placebo-treated patients).
- The proportion of patients treated with Enbrel who developed anticardiolipin antibodies was similarly increased compared to placebo-treated patients.
- In RA Study III, no pattern of increased autoantibody development was seen in Enbrel patients compared to MTX patients.
Adverse reactions have been reported during post approval use of Enbrel in adults and pediatric patients. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to Enbrel exposure.
Adverse reactions are listed by body system below:
- Blood and lymphatic system disorders: pancytopenia, anemia, leukopenia, neutropenia, thrombocytopenia, lymphadenopathy, aplastic anemia
- Cardiac disorders: congestive heart failure
- Gastrointestinal disorders: inflammatory bowel disease (IBD)
- General disorders: angioedema, chest pain
- Hepatobiliary disorders: autoimmune hepatitis, elevated transaminases, hepatitis B reactivation
- Immune disorders: macrophage activation syndrome, systemic vasculitis, sarcoidosis
- Musculoskeletal and connective tissue disorders: lupus-like syndrome
- Neoplasms benign, malignant, and unspecified: melanoma and non-melanoma skin cancers, Merkel cell carcinoma
- Nervous system disorders: convulsions, multiple sclerosis, demyelination, optic neuritis, transverse myelitis, paresthesias
- Ocular disorders: uveitis, scleritis
- Respiratory, thoracic and mediastinal disorders: interstitial lung disease
- Skin and subcutaneous tissue disorders: cutaneous lupus erythematosus, cutaneous vasculitis (including leukocytoclastic vasculitis), erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, subcutaneous nodule, new or worsening psoriasis (all sub-types including pustular and palmoplantar)
Opportunistic infections, including atypical mycobacterial infection, herpes zoster, aspergillosis and Pneumocystis jiroveci pneumonia, and protozoal infections have also been reported in postmarketing use.
What drugs interact with Enbrel (etanercept)?
Specific drug interaction studies have not been conducted with Enbrel.
- Most PsA patients receiving Enbrel were able to mount effective B-cell immune responses to pneumococcal polysaccharide vaccine, but titers in aggregate were moderately lower and fewer patients had 2-fold rises in titers compared to patients not receiving Enbrel.
- The clinical significance of this is unknown. Patients receiving Enbrel may receive concurrent vaccinations, except for live vaccines.
- No data are available on the secondary transmission of infection by live vaccines in patients receiving Enbrel.
- Patients with a significant exposure to varicella virus should temporarily discontinue Enbrel therapy and be considered for prophylactic treatment with varicella zoster immune globulin.
Immune-Modulating Biologic Products
- In a study in which patients with active RA were treated for up to 24 weeks with concurrent Enbrel and anakinra therapy, a 7% rate of serious infections was observed, which was higher than that observed with Enbrel alone (0%) and did not result in higher ACR response rates compared to Enbrel alone.
- The most common infections consisted of bacterial pneumonia (4 cases) and cellulitis (4 cases).
- One patient with pulmonary fibrosis and pneumonia died due to respiratory failure.
- Two percent of patients treated concurrently with Enbrel and anakinra developed neutropenia (ANC < 1 x 109/L).
- In clinical studies, concurrent administration of abatacept and Enbrel resulted in increased incidences of serious adverse events, including infections, and did not demonstrate increased clinical benefit.
- The use of Enbrel in patients receiving concurrent cyclophosphamide therapy is not recommended.
- Patients in a clinical study who were on established therapy with sulfasalazine, to which Enbrel was added, were noted to develop a mild decrease in mean neutrophil counts in comparison to groups treated with either Enbrel or sulfasalazine alone.
- The clinical significance of this observation is unknown.
Multimedia: Slideshows, Images & Quizzes
Psoriasis Types, Images, Treatments
What is psoriasis? See examples of psoriasis including the different types of nail, plaque, and scalp psoriasis. Learn about...
What Is Rheumatoid Arthritis (RA)? Symptoms, Treatment, Diagnosis
What is rheumatoid arthritis (RA)? Learn about treatment, diagnosis, and the symptoms of juvenile rheumatoid arthritis. Discover...
Home Remedies for Psoriasis
Discover home remedies for psoriasis and help heal irritated skin.
Types of Psoriasis: Medical Pictures and Treatments
Explore the different types of psoriasis such as plaque psoriasis, inverse psoriasis, and scalp psoriasis. Discover what causes...
Psoriatic Arthritis Symptoms, Treatment, Diagnosis
Psoriatic arthritis pain can be treated. Get more information on the causes, symptoms, diagnosis, and medications for psoriatic...
Rheumatoid Arthritis Exercises: Joint-Friendly Workouts
Regular exercise boosts fitness and helps reverse joint stiffness for people with rheumatoid arthritis (RA). WebMD demonstrates...
Psoriasis: Top 10 Causes, Triggers and Treatments
Psoriasis triggers a red, scaly rash of plaques on the skin typically affecting the elbows, knees, and scalp. Treatment involves...
Ankylosing Spondylitis: Symptoms, Diagnosis, and Treatment
What is ankylosing spondylitis (AS)? Ankylosing spondylitis is arthritis of the spine. Learn diet and exercise tips for AS, and...
Ankylosing Spondylitis Quiz: Symptoms & Treatment
What is ankylosing spondylitis? Take this quiz to learn the causes, symptoms, and treatments for this painful disorder.
Psoriasis Quiz: Test Your Medical IQ
Take the mystery out of psoriasis. Take the Psoriasis Quiz and see what you know about the types, symptoms, treatments and more.
Psoriatic Arthritis Quiz: Test Your Medical IQ
How is psoriatic arthritis related to psoriasis? Take this quiz to find out!
Rheumatoid Arthritis Quiz: What is Rheumatoid Arthritis?
How is rheumatoid arthritis different from other forms of arthritis, such as osteoarthritis and gout? Take the Rheumatoid...
Picture of Psoriasis 1
A reddish, scaly rash often located over the surfaces of the elbows, knees, scalp, and around or in the ears, navel, genitals or...
Picture of Psoriasis 2
More than one-quarter of all individuals with psoriasis develop their disease during childhood or adolescence. See a picture of...
Picture of Psoriasis 3
This figure shows the erythema, scaling, and thickening of portions of the thumb and soles that are very common in both children...
Picture of Pustular Psoriasis
Pustular psoriasis is an uncommon form of psoriasis. See a picture of Pustular Psoriasis and learn more about the health topic.
Picture of Erythrodermic Psoriasis
This is the least common type of psoriasis and can be quite serious. See a picture of Erythrodermic Psoriasis and learn more...
Picture of Psoriatic Arthritis
Psoriatic arthritis is a specific condition in which a person has both psoriasis and arthritis. See a picture of Psoriatic...
Famous Faces With Rheumatoid Arthritis
Learn more about the famous faces of rheumatoid arthritis such as Lucille Ball, Glenn Frey, and more.
Related Disease Conditions
Psoriasis is a long-term skin condition that may cause large plaques of red, raised skin, flakes of dry skin, and skin scales. There are several types of psoriasis, including psoriasis vulgaris, guttate psoriasis, inverse psoriasis, and pustular psoriasis. Symptoms vary depending on the type of psoriasis the patient has. Treatment of psoriasis may include creams, lotions, oral medications, injections and infusions of biologics, and light therapy. There is no cure for psoriasis.
Rheumatoid Arthritis (RA)
Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints, the tissue around the joints, as well as other organs in the body. Because it can affect multiple other organs of the body, rheumatoid arthritis is referred to as a systemic illness and is sometimes called rheumatoid disease. The 16 characteristic early RA signs and symptoms include the following. Anemia Both sides of the body affected (symmetric) Depression Fatigue Fever Joint deformity Joint pain Joint redness Joint stiffness Joint swelling Joint tenderness Joint warmth Limping Loss of joint function Loss of joint range of motion Many joints affected (polyarthritis)
16 Early Rheumatoid Arthritis (RA) Symptoms and Signs
Early RA symptoms and signs vary differently from person to person. The most common body parts that are initially affected by RA include the small joints of the hands, wrists, and feet, and the knees and hip joints. Joint inflammation causes stiffness. Warmth, redness, and pain may vary in degree.
Ankylosing spondylitis is a type of arthritis that causes chronic inflammation of the spine. The tendency to develop ankylosing spondylitis is genetically inherited. Treatment incorporates medications, physical therapy, and exercise.
Rheumatoid Arthritis vs. Fibromyalgia
Though rheumatoid arthritis (RA) and fibromyalgia have similar symptoms, RA is an autoimmune disease and fibromyalgia is a chronic pain syndrome. RA symptoms include joint redness, swelling, and pain that lasts more than six weeks. Fibromyalgia symptoms include widespread pain, tingling feet or hands, depression, and bowel irritability. Home remedies for both include stress reduction, exercise, and getting enough sleep.
Pain Management and Rheumatoid Arthritis
Second Source article from WebMD
Second Source article from Government
Scalp Psoriasis (Psoriasis of the Scalp)
Scalp psoriasis causes red, raised, scaly patches that may extend from the scalp to the forehead and the back of the neck and ears. Symptoms and signs include itching, hair loss, flaking, silvery scales, and red plaques. Treatment includes topical medicated shampoos, creams, gels, oils, ointments, and soaps, medications, and light therapy.
What Is the Best Treatment for Psoriasis?
Psoriasis is an incurable chronic autoimmune disorder of the skin that causes patches of thick, flaky, scaly skin, mostly around the scalp, knees, and elbows, though any skin surface may be involved. Some people experience only small patches while others have red, inflamed skin and think scaly patches all over the body. The exact cause of psoriasis is not clear, but it isn’t contagious.
Can Rheumatoid Arthritis Be Caused by Stress?
Rheumatoid arthritis is a chronic inflammatory joint condition and an autoimmune disease. At times, treatment can make rheumatoid arthritis symptoms (pain and swelling) disappear for a while. This symptom-free period is referred to as “remission.” A remission is followed by the reappearance of symptoms and this period is known as a flare-up. Research says that rheumatoid arthritis can be caused by stress.
Rheumatoid Arthritis vs. Arthritis
Arthritis is a general term used to describe joint disease. Rheumatoid arthritis (RA) is a type of arthritis in which the body’s immune system mistakenly attacks the joints, causing chronic inflammation.
Is Psoriasis Contagious?
Psoriasis is an incurable skin disease that causes reddish patches of skin topped with a thick layer of dry silvery scales. Psoriasis cannot spread and is not contagious.
What Is the Main Cause of Psoriasis?
Psoriasis is a non-contagious skin disease in which the skin cells grow in numbers faster than normal, producing rashes on the body. Normally, the cells on the surface of the skin are shed as new cells grow beneath. In psoriasis, the swift build-up of skin cells collects on the surface of the skin as scales or plaques. The exact cause of psoriasis is not completely understood. It appears to involve an interplay between a person’s genes, immune system and environment.
How Serious Is Rheumatoid Arthritis?
Rheumatoid arthritis (RA) is a chronic inflammatory disorder that typically affects the joints and other body parts, such as the skin, eyes, lungs, heart and blood vessels. RA is an autoimmune disorder, a condition where the body’s immune system attacks its own tissues. If not diagnosed early and appropriately treated, RA can lead to permanent deformities, disabilities and serious systemic complications.
Juvenile Rheumatoid Arthritis (JRA)
Juvenile rheumatoid arthritis (JRA) annually affects one child in every thousand. There are six types of JRA. Treatment of juvenile arthritis depends upon the type the child has and should focus on treating the symptoms that manifest.
What Are the Four Stages of Rheumatoid Arthritis?
Rheumatoid arthritis is a chronic inflammatory disease characterized by pain and inflammation in joints, typically of the hands and feet. It is an autoimmune disease in which the immune system of the body attacks its own healthy cells, resulting in inflammation of the membrane lining the joints and damage to joint tissue.
What Triggers Ankylosing Spondylitis?
Ankylosing spondylitis (AS), also called Bechterew disease, is a chronic inflammatory disease. Ankylosing spondylitis affects the joints of the body, especially the small joints of the spine and the pelvic (hip) bone. It can also affect multiple organ systems in rare conditions. Prolonged inflammation of the joints eventually leads to the fusion of the joints leading to deformities.
How to Get Rid of Psoriasis Quickly
Although psoriasis is incurable, it responds to topical and systemic treatments. Topical treatments that may be effective to treat mild psoriasis include creams, lotions, and sprays.
Breastfeeding With Rheumatoid Arthritis
You can breastfeed your baby even if you have rheumatoid arthritis (RA). However, you must always consult your doctor before you start the process.
Safest Rheumatoid Arthritis Drugs During Pregnancy
None of the drugs used in the treatment of rheumatoid arthritis (RA) is completely safe during pregnancy. You must discuss with your physician regarding the decision to use, modify, or stop any medications.
Osteoarthritis vs. Rheumatoid Arthritis
Osteoarthritis (OA) and rheumatoid arthritis (RA) are chronic joint disorders. RA is also an autoimmune disease. OA and RA symptoms and signs include joint pain, warmth, and tenderness. Over-the-counter pain relievers treat both diseases. There are several prescription medications that treat RA.
How Do You Stop Psoriasis From Stress?
Psoriasis is an autoimmune skin disease that can be passed down (hereditary) to you from your parents or grandparents. Stress is a common factor that can trigger your psoriasis. Psoriasis has a stronger association with psychiatric disorders than other skin diseases. Stress worsens psoriasis by triggering a complex network of signals between the endocrine (hormones), nervous and immune systems.
Can Rheumatoid Arthritis Affect Pregnancy?
Yes, rheumatoid arthritis (RA) affects pregnancy. RA can lead to complications like preterm birth, raised blood pressure (preeclampsia), and low birth weight babies.
Causes of Rheumatoid Arthritis
Rheumatoid arthritis (RA) is an autoimmune disorder (the body’s immune system mistakenly attacks its own cells). Certain factors increase the risk of RA.
Treatment & Diagnosis
- Rheumatoid Arthritis FAQs
- Psoriasis FAQs
- Ankylosing Spondylitis FAQs
- Psoriatic Arthritis FAQs
- Rheumatoid Arthritis vs. Osteoarthritis
- Rheumatoid Arthritis (RA): 17 Warning Signs of Serious Complications
- Is HCQ Safe For Pregnant Women With Rheumatoid Arthritis (RA)?
- Why Does Pregnancy Affect the Course of Rheumatoid Arthritis (RA)?
- Can Rituximab Be Taken By Breastfeeding Women With Rheumatoid Arthritis?
- Are Corticosteroids Safe for Pregnant and Nursing Women with Rheumatoid Arthritis?
- Is Anakinra (Kineret) Safe for Pregnant Women with Rheumatoid Arthritis (RA)?
- How Does Pregnancy Affect the Course of Rheumatoid Arthritis (RA)?
- What if I get COVID-19 with Rheumatoid Arthritis?
- 5 Surprising Facts About Rheumatoid Arthritis
- Patient Story: Rheumatoid Arthritis and Pregnancy
- Rheumatoid Arthritis: Questions for Your Doctor
- Kineret (anakinra) for Rheumatoid Arthritis
- Treatment Update on Rheumatoid Arthritis
- Psoriasis, Lupus, Rheumatoid Arthritis Share One Gene
- Psoriasis Drugs Strike Immune Targets (Raptiva, Enbrel)
- Rheumatoid Arthritis & Diabetes Gene (PTPN22)
- Arava Approved For Rheumatoid Arthritis
- Smoking: A New Risk - Rheumatoid Arthritis
- Ankylosing Spondylitis and Pregnancy
- Cox-2 Inhibitors, What's Next? - Expert Panel Votes
- Patient Story: Rheumatoid Arthritis Symptoms
- Rheumatoid Arthritis Joint Symptoms and Signs: What Do They Mean?
- Rheumatoid Arthritis: Which Patients Do Best?
- Ultrasound Imaging of Joints in Rheumatoid Arthritis (RA)
- Living With Rheumatoid Arthritis
- How Does Ankylosing Spondylitis Affect Eyes and How Is It Treated?
- Is Inflammatory Arthritis the Same as Rheumatoid Arthritis?
- Can You Have Ankylosing Spondylits Without the HLA-B27 Gene?
- Can Milk Allergy Cause Rheumatoid Arthritis?
- Can You Get Gout in Your Back?
- What Are the Side Effects of Remicade for Rheumatoid Arthritis?
- Can Radiation Treat Ankylosing Spondylitis?
- Should You Avoid Drinking Soda with Rheumatoid Arthrits?
- Do Crohn's Patients Get a Specific Type of Arthritis?
- Are Hidradenitis and Rheumatoid Arthritis Related?
- How Do You Get Psoriasis?
- Can Psoriasis Be Caused by Allergy?
- Is It Eczema or Psoriasis?
- What Are the Triggers of Psoriasis?
- What Are the Side Effects of Prednisone for Ankylosing Spondylitis?
- Does Lipitor Help Rheumatoid Arthritis?
- Will Rheumatoid Arthritis Nodules Go Away?
- What's the Rheumatoid Arthritis Prognosis?
- What Are Home Remedies for Rheumatoid Arthritis?
- Patient Story: Rheumatoid Arthritis Treatment
- Rheumatoid Arthritis: Living With a Chronic Disease
- Psoriasis PUVA Therapy Can Increase Melanoma Risk
- Rheumatoid Arthritis - Checking Your Pulse Audio Segment
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Professional side effects and drug interactions sections courtesy of the U.S. Food and Drug Administration.